Feed ATAI
AT

Atai Life Sciences N.V.

ATAI · NASDAQ

$7.35 +0.68% (+$0.05)
1M -0.41%
Market Cap $2.72B
P/E Ratio -
Div. Yield 91.84%
ROE 353.23%
Piotroski F-Score Moderate
5/9
Valuation
0 /100
Expensive
P/B 15.42x
P/S 607.91x
EV/EBITDA N/A
Growth
78 /100
Growing
Book val. growth 5.24%
Rev. growth 159.87%
FCF growth N/A
Profitability
20 /100
Weak
Net margin 14,938.40%
Op. margin 3,274.31%
FCF margin 2,978.78%
Quality
0 /100
Poor
ROE 353.23%
ROA 252.35%
Asset turnover 0.02x
Debt
100 /100
Low
Current ratio 8.58x
Debt/Equity 0.02x
Net debt/EBITDA N/A
Stability
8 /100
Unstable
Rev. volatility 699.51%
EPS volatility 185.36%
Profitable years 0

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre ATAI
Online

Despre companie

Atai Life Sciences N.V. (ATAI) is a biotechnology company focused on research and development of novel therapeutic approaches in the field of mental health and psychiatric disorders. The company focuses on innovative therapies and drugs that have the potential to treat or improve the lives of people suffering from various mental illnesses, including depression, anxiety, post-traumatic stress disorder, addictions, and other disorders. Atai Life Sciences actively collaborates with other research institutions and biotechnology companies and invests in projects with the hope of discovering new treatment options. Their goal is to bring new drugs and therapies to the market that can make a significant difference for patients with mental disorders. Atai Life Sciences N.V. (ATAI) shares may be an attractive investment opportunity for investors interested in the biotechnology sector and seeking an investment in a company focusing on innovative therapeutic approaches in the field of mental health.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Srinivas G. Rao

Employees

99

Headquarters

New York

Evenimente viitoare

12 NOV.

Earnings

Upcoming earnings report

51d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.